What is Akkermansia Muciniphila?
Akkermansia muciniphila is a gram-negative, anaerobic bacterium that naturally inhabits the human intestinal tract. Classified within the Verrucomicrobia phylum, it was first identified in 2004 and has since become one of the most extensively studied members of the gut microbiota.
In scientific research, Akkermansia muciniphila has been described as a “next-generation probiotic” candidate because of its unique role in maintaining gut microbial balance. Its natural presence in the mucus layer of the intestine has made it an important focus in microbiome science, functional nutrition, and innovative probiotic product development.
Applications of Akkermansia Muciniphila
Nutritional Supplements
Increasingly used in next-generation probiotic formulations, offering product differentiation beyond traditional Lactobacillus and Bifidobacterium strains.
Provides opportunities for companies to position products in the premium segment of microbiome-focused supplements.
Functional Foods & Beverages
Incorporated into food products designed for gut microbiota innovation, responding to consumer demand for advanced health ingredients.
Supports the growing market of functional nutrition targeting the gut ecosystem.
Research & Development
Widely used in academic and industrial microbiome research to study host–microbe interactions, mucosal biology, and metabolic pathways.
Provides valuable material for clinical studies and next-generation probiotic development.
(If you would like to learn more about probiotic ingredients, please feel free to contact us.)
Legal Background & Safety
The regulatory landscape for Akkermansia muciniphila is evolving, and compliance remains a critical factor for companies entering the market:
European Union (EU): In 2021, pasteurised Akkermansia muciniphila received novel food approval by the European Commission, authorising its use in food supplements for adults.
United States: Live strains are not yet classified as GRAS (Generally Recognized As Safe), but research and regulatory evaluation are ongoing.
Other Markets: Jurisdictions such as China and Asia-Pacific are closely monitoring EU developments, with regulatory pathways under assessment.
Safety studies, including human clinical trials, suggest that pasteurised strains are well tolerated, which strengthens its potential as a future commercial ingredient. Companies must ensure that any commercial use strictly follows local regulatory guidelines.
Why Choose Akkermansia Muciniphila from Natural Micron Pharm?
High-Quality Supply – Available in pasteurised and research-grade forms, manufactured under strict quality standards.
Regulatory Support – Guidance provided for compliance with EU novel food frameworks and global regulations.
Comprehensive Documentation – COA, TDS, SDS, and technical data available for all batches.
Flexible Solutions – Supply tailored for supplement developers, food manufacturers, and R&D institutions.
By choosing Natural Micron Pharm, you gain a reliable partner for sourcing Akkermansia muciniphila and developing innovative products that meet industry demand.
📩 Contact us today to request product specifications, pricing, or samples for your formulation pipeline.
FAQs
Q1: Is Akkermansia Muciniphila approved for use in supplements?
Yes, in the EU pasteurised Akkermansia muciniphila is authorised as a novel food under defined conditions. Other markets may have different rules.
Q2: What forms are available for supply?
We provide pasteurised strains suitable for supplements and research-grade materials for academic and industrial R&D.
Q3: Why is Akkermansia Muciniphila called a “next-generation probiotic”?
Because it goes beyond traditional strains (Lactobacillus, Bifidobacterium) and reflects the latest microbiome science and innovation.
Q4: What documentation do you provide?
COA, TDS, SDS, and regulatory support documents are available upon request.
